NYSE$CTVA
Corteva Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Corteva reported strong sales growth and made progress on portfolio actions.
Corteva's third quarter results showed a 17% increase in net sales and a significant improvement in Operating EBITDA, driven by focused global execution and strong customer demand. The company is progressing with portfolio actions, including the acquisition of Symborg and the decision to exit commodity glyphosate products. Looking ahead to 2023, the company expects a dynamic operating environment with macroeconomic pressures, but remains focused on executing its strategic plan and serving customers.
- Net sales increased by 17% compared to the same period last year.
- Organic sales rose by 22%, with double-digit increases in all regions.
- Operating EBITDA increased to $96 million, up from a loss of $51 million in the year-ago period.
- The company signed an agreement to acquire Symborg and made a business decision to exit commodity glyphosate products.
Headline financials
Revenue & EPS history
Corteva · Revenue · Quarterly
$2.78B
Revenue by segment
Corteva · $2.78B total across 2 segments · Q3 2022
- Crop Protection$1.92B+17.3%69.0%
- Seed$862M+16.8%31.0%
Forward guidance
Corteva affirmed full year 2022 net sales guidance of $17.2 billion to $17.5 billion and increased the mid-point of its Operating EBITDA guidance to be in the range of $3.0 billion to $3.1 billion. Operating EPS is expected to be in the range of $2.45 to $2.60 per share.
Tailwinds
- The Company expects record demand for grain and oilseeds in 2022, which should support commodity prices as ending stocks remain under pressure.
- Grower balance sheets and income levels remain healthy despite increased input costs for fuel and fertilizer, leading farmers to prioritize technology to maximize return.
- Affirmed full year 2022 net sales guidance of $17.2 billion to $17.5 billion.
- Increased the mid-point of its Operating EBITDA guidance, and now expects it to be in the range of $3.0 billion to $3.1 billion.
- Operating EPS is expected to be in the range of $2.45 to $2.60 per share.
Headwinds
- The Company is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures.
- The outlook for agriculture remains robust despite recent commodity price volatility.
- Macroeconomic pressures are expected to continue, including currency and inflation headwinds.
- The company expects an approximate $300 million headwind to net sales related to commodity glyphosate products in 2023.
- Unfavorable currency impacts were led by the South African Rand and the Euro.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.1%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.0%
Avg return
30 days after
59%
20 / 34 earnings
Positive
+18.0%
Q4 2023
Best reaction
-13.9%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -3.5% | -8.1% | |
| Q4 2025 | +0.9% | -1.9% | +2.6% | |
| Q3 2025 | +1.8% | +4.9% | +5.6% | |
| Q2 2025 | -0.2% | +1.8% | +1.8% | |
| Q1 2025 | +7.0% | +8.7% | +14.7% | |
| Q4 2024 | -2.3% | -1.3% | -5.1% | |
| Q3 2024 | -5.0% | -5.2% | -3.7% | |
| Q2 2024 | -4.6% | -7.6% | +3.2% | |
| Q1 2024 | +5.3% | +4.1% | +3.3% | |
| Q4 2023 | +18.0% | +13.0% | +17.1% | |
| Q3 2023 | -9.7% | -8.1% | -8.4% | |
| Q2 2023 | +0.2% | -3.1% | -8.6% | |
| Q1 2023 | -6.2% | -5.0% | -7.8% | |
| Q4 2022 | -3.8% | -5.8% | -1.2% | |
| Q3 2022 | -2.3% | +0.4% | +0.6% | |
| Q2 2022 | +3.9% | +7.2% | +9.9% | |
| Q1 2022 | +1.4% | -7.3% | +8.3% | |
| Q4 2021 | +1.3% | +3.4% | +7.4% | |
| Q3 2021 | +10.6% | +8.6% | +7.5% | |
| Q2 2021 | +5.9% | +7.9% | +6.3% | |
| Q1 2021 | -4.1% | -1.7% | -7.5% | |
| Q4 2020 | +2.8% | +5.1% | +8.1% | |
| Q3 2020 | +3.1% | +5.2% | +17.4% | |
| Q2 2020 | -11.3% | -6.2% | +2.7% | |
| Q1 2020 | +1.0% | -6.9% | +17.1% | |
| Q3 2017 | +2.6% | +3.0% | -18.9% | |
| Q4 2017 | +2.6% | +3.0% | -18.9% | |
| Q4 2019 | +4.0% | +11.3% | -2.2% | |
| Q3 2018 | -4.7% | -6.6% | -5.3% | |
| Q3 2019 | -4.7% | -6.6% | -5.3% | |
| Q2 2018 | +2.5% | +5.8% | -4.8% | |
| Q2 2019 | +6.6% | +1.9% | -0.6% | |
| Q1 2019 | -13.9% | -2.7% | +2.7% | |
| Q4 2018 | -13.9% | -2.7% | +2.7% | |
| Q1 2018 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro